ClinicalTrials.gg
RecruitingNCT06068530MVDAUpdated Dec 18, 2025

Mass Vaccine and Drug Administration, Bangladesh

A Phase 4 interventional study of DHA/piperaquine and a SLD-PQ and Study vaccine R21/Matrix-M™ in Plasmodium Falciparum Malaria, sponsored by University of Oxford. Recruiting at 2 sites in Bangladesh. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by University of Oxford · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10,000
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Malaria, Falciparum by University of Oxford — 3 open to participants now, 9 under way, 1 of them phase 3. Malaria, Falciparum · University of Oxford.

Planned enrollment
Largest of 47
10,000 · median 62
Started
2025
with 4 others
Phase 4
3 of 54
2 open now
Registered
48th of 54
by date

Among the 54 studies in Malaria, Falciparum by University of Oxford, this one has the largest planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 4, and was the 48th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

3 of the 54 studies in Malaria, Falciparum by University of Oxford are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Malaria, Falciparum by University of Oxford, or all of them as a file.
02

Study summary

This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the current standard of care.

Read the detailed description

Trial Activities: The investigators are most interested in the combined effect of mass administration of vaccines and drugs on malaria transmission. Can Mass Vaccine and Drug Administrations (MVDA) reduce the parasite prevalence in intervention villages compared to control villages which did not receive the intervention? The entire village population will be enrolled at study start and followed for two years after D0, the first day of the interventions in the intervention villages. The village population is a dynamic cohort with new members entering the cohort by birth or immigration and other members leaving the cohort due to emigration or death. Newcomers entering villages will receive MVDA as soon as feasible and as appropriate (dependent on age). Secondly, the investigators want to know how effective the individual components of the intervention, mass vaccinations and mass drug administrations are in relation to MVDA?

Hanako Foundation funded this study. Grant reference number: B9R05700

03

Conditions studied

  • Plasmodium Falciparum Malaria

Browse trials for

Keywords

  • Plasmodium Falciparum Malaria
  • Malaria Vaccine
  • Malaria Drug Administrations
04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current residence in a study village irrespective of permanence
  • Age 6 months and above (no upper age limit)
  • Written provided by participants (or a parent/guardian in case the participant is under 18 years old)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, plan to get pregnant, or breastfeeding.
  • Acute illness requiring intervention
  • A history of an adverse reaction to study drugs/vaccine and prior receipt of any other malaria vaccine or enrolment in another intervention trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10,000 participants (estimated)

Study arms

  • Active comparator
    MDA + Vaccine

    The participants in MVDA villages will receive R21/Matrix M at M0, M1, M2, and a booster M12 plus DHA/piperaquine and a SLD-PQ at M0, M1, and M2

    Drug: DHA/piperaquine and a SLD-PQ · Biological: Study vaccine R21/Matrix-M™

  • Active comparator
    MDA only

    The participants in MDA only villages will receive DHA/piperaquine and a SLD-PQ at M0, M1, and M2

    Drug: DHA/piperaquine and a SLD-PQ

  • Active comparator
    Vaccine only

    The participants in vaccine only villages will receive R21/Matrix M at M0, M1, M2, and a booster M12

    Biological: Study vaccine R21/Matrix-M™

  • No intervention
    Control

    The participants in control will receive MVDA at the end of the 24th month assuming that MVDA is found to be safe and effective. During M0 to M24, the comparison villages will receive the standard of care as per national malaria treatment guidelines.

Interventions

  • DrugDHA/piperaquine and a SLD-PQ

    Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.

  • BiologicalStudy vaccine R21/Matrix-M™

    The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.

06

What researchers measure

Primary outcomes

  1. Falciparum malaria incidence by study groups

    Falciparum malaria incidence will be determined by the number of clinical falciparum malaria cases confirmed by Rapid diagnostic test (RDT) or microscopy to determine the overall protective efficacy against clinical falciparum malaria among study groups. The investigators will look for the presence of axillary temperature ≥37.5°C AND P. falciparum positive RDT or microscopy as a primary case definition of clinical falciparum malaria.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  2. Falciparum malaria prevalence by study groups

    Falciparum malaria prevalence will be determined by the number of positive falciparum confirmed by dried blood spots (DBS) polymerase chain reaction (PCR) malaria detection method during cross-sectional surveys to determine the overall protective efficacy against subclinical P. falciparum among study groups. * The investigators will collect dried blood spots to detect malaria during cross-sectional surveys from the healthy participants. * Those who have axillary temperature ≥37.5°C AND P. falciparum positive RDT or microscopy will receive treatment according to national treatment guidelines.

    Time frame: PCR for malaria detection from DBS will be collected at 6th month intervals until two years following baseline intervention (Month 0, Month 6, Month 12, Month 18 and Month 24)

  3. Overall percentage of falciparum malaria positivity by study groups

    The percentage of falciparum malaria positivity will be determined by the number of falciparum positives detected by PCR, RDT or microscopy to determine overall protective efficacy against clinical and subclinical falciparum malaria among study groups. Dried blood spots to detect malaria from by PCR will be collected at baseline and every six months until two years. Clinical malaria data detected by rapid diagnostic test or microscopy will be collected for two years following intervention. * The investigators will look for the presence of axillary temperature ≥37.5°C AND P. falciparum positive RDT or microscopy as a primary case definition of clinical malaria. * The investigators will collect dried blood spots to detect malaria during cross-sectional surveys from the healthy participants.

    Time frame: DBS: Month 0, Month 6, Month 12, Month 18 and Month 24 and Clinical malaria data for two year following intervention

Secondary outcomes

  1. The incidence of Deaths related to falciparum malaria among study groups

    The number of Deaths related to falciparum malaria (confirmed by RDT or microscopy) will be recorded for two year following intervention. Death rate among study groups will be compared

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  2. The incidence of severe malaria disease among study groups

    The number of Severe malaria diseases (according to WHO criteria) will be recorded for two years following intervention and the incidences will be compared among study groups. Primary case definition of severe malaria: * Presence of P. falciparum (RDT positive or microscopy positive); AND one of more of the following criteria of disease severity: * Prostration * Respiratory distress * Blantyre coma score ≤ 3 * Seizures: 2 or more * Hypoglycemia \< 2.2 mmol/L * Acidosis BE ≤-8.0 mmol/L * Lactate ≥ 5.0 mmol/L * Anemia \< 5.0 g/dL * Acute kidney injury * Pulmonary oedema * Significant bleeding * Shock (systolic BP \<70mm Hg); AND Without any of the following criteria of co- morbidity * Pneumonia (confirmed by X-ray) * Meningitis (confirmed by CSF examination) * Sepsis (with Positive blood culture) * Gastroenteritis with dehydration

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  3. The incidence of severe anaemia among study groups

    The number of severe anemia cases will be recorded for two years following interventions among all participants and the proportions will be compared among study groups Severe anaemia due to severe malaria according to WHO criteria * Anaemia \< 5.0 g/dL * Requires blood transfusion according to National guidelines

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  4. Vivax malaria incidence by study groups

    Vivax malaria incidence will be determined by the number of clinical vivax malaria cases confirmed by RDT or microscopy to determine the overall protective efficacy against clinical vivax malaria among study groups. The investigators will look for the presence of axillary temperature ≥37.5°C AND P.vivax positive RDT or microscopy as a primary case definition of clinical vivax malaria.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  5. Vivax malaria prevalence by study groups

    Vivax malaria prevalence will be determined by the number of positive vivax confirmed by dried blood spots PCR malaria detection method during cross-sectional surveys to determine the overall protective efficacy against subclinical P. vivax among study groups. * The investigators will collect dried blood spots to detect malaria during cross-sectional surveys from the healthy participants. * Those who have axillary temperature ≥37.5°C AND P. vivax positive RDT or microscopy will receive treatment according to national treatment guideline.

    Time frame: PCR for malaria detection from DBS will be collected at 6th month intervals until two years following baseline intervention (Month 0, Month 6, Month 12, Month 18 and Month 24)

  6. Overall percentage of vivax malaria positivity by study groups

    The percentage of vivax malaria positivity will be determined by the number of vivax positives detected by PCR, RDT or microscopy to determine overall protective efficacy against clinical and subclinical vivax malaria among study groups. Dried blood spots to detect malaria from by PCR will be collected at baseline and every six months until two years. Clinical malaria data detected by rapid diagnostic test or microscopy will be collected for two years following intervention. * The investigators will look for the presence of axillary temperature ≥37.5°C AND P. vivax positive RDT or microscopy as a primary case definition of clinical malaria. * The investigators will collect dried blood spots to detect malaria during cross-sectional surveys from the healthy participants.

    Time frame: DBS: Month 0, Month 6, Month 12, Month 18 and Month 24 and Clinical malaria data for two year following intervention

  7. The incidence of adverse events

    The number of events will be assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 among all participants and compared among study groups to determine the safety and reactogenicity * Occurrence of solicited local and/or systemic reactogenicity signs and symptoms for 7 days following the intervention ((a) R21 adjuvanted with Matrix-M b) mass drug administration with DHA/piperaquine plus SLDPQ c) vaccine and MDA combined) * Occurrence of unsolicited adverse events for 28 days following the intervention * Occurrence of serious adverse events for the duration of the trial

    Time frame: All adverse events which occur after administration of the first dose of the study drugs until one month after last dose of drugs or vaccine will be recorded. This data will be collected from Month 0 to month 24.

  8. The concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-NANP total IgG antibody) among subset of randomly selected participants from vaccinated and no intervention group.

    * Comparison of immunogenicity (antibody responses to CSP) in the R21/MM vaccination group with those in the a) combined group vaccine plus MDA b) control group (mass drug administration with DHA/piperaquine plus SLDPQ) * ELISA to quantify antibodies to the vaccine components (regions of the CS antigen including the NANP repeat region and other elements of the protein as well as anti HBs)

    Time frame: One month after the completion of the third dose (at Study month 3), and one month after the booster dose (at Study Month 13)

  9. Prevalence of molecular markers for drug resistant P. falciparum

    The presence (Number) of molecular markers for drug resistant P. falciparum such as Kelch 13 mutations, plasmepsin 2 and mdr1 will be measured from DBS samples for all falciparum positive cases to determine the prevalence among test participants in each study group.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  10. The acceptability of the intervention will be assessed by coverage (The number of residents participating in the interventions) reported as percentage of the target population participating in the intervention.

    Time frame: Month 3 and Month 13

  11. The acceptability of the intervention will be assessed by mixed social science methods, in depth interviews and Focus group discussions.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  12. The incidence of clinical falciparum malaria confirmed by RDT or microscopy among vaccinated and drug administered participants in compare to unvaccinated and no drug-administered participants living in standard-of-care villages.

    To determine the direct protective efficacy of the combined intervention MVDA against falciparum malaria infection. Data on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  13. The incidence of clinical falciparum malaria confirmed by RDT or microscopy among vaccinated participants in compare to unvaccinated participants living in standard-of-care villages.

    To determine direct protective efficacy of the vaccination alone against falciparum malaria infection. Data on falciparum malaria infection confirmed by RDT or microscopy will be collected to measure incidence.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  14. The incidence of clinical falciparum malaria confirmed by RDT or microscopy among drug administered participants in compare to no drug-administered participants living in standard-of-care villages.

    To determine direct protective efficacy of the mass drug administration alone against falciparum malaria infection. Data on falciparum malaria infection confirmed by RDT or microscopy will be collected to measure incidence.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  15. The incidence of clinical falciparum malaria confirmed by RDT or microscopy among unvaccinated and no drug-administered people living in intervention clusters relative to unvaccinated and no drug-administered people living in standard-of-care villages.

    To determine indirect protective efficacy of the combined intervention MVDA observed against falciparum malaria infection. Data on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  16. The incidence of clinical falciparum malaria confirmed by RDT or microscopy among unvaccinated people living in intervention clusters relative to unvaccinated people living in standard-of-care villages.

    To determine Indirect protective efficacy of the vaccination alone observed against falciparum malaria infection. Data on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

  17. The incidence of clinical falciparum malaria confirmed by RDT or microscopy among no drug-administered people living in intervention clusters relative to no drug-administered people living in standard-of-care villages.

    To determine indirect protective efficacy of the mass drug administration alone observed against falciparum malaria infection. Data on falciparum malaria infection confirmed by RDT or microscopy will be collected and measured.

    Time frame: Data will be collected for two years following baseline intervention (Month 0 to Month 24)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — With participant's consent, participant's data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with data repositories such as the WorldWide Antimalarial Resistance Network (WWARN, terms of submission here: http://www.wwarn.org/tools-resources/terms-submission) or other researchers to use in the future. All personal information will be anonymised so that no individual can be identified from their treatment records, through interviews, or from mapping data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 35 months after the start.

Of 23 phase 4 interventional studies under Malaria, Falciparum, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2023
First posted
Oct 5, 2023
StartActual
Feb 15, 2025
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06068530
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Feb 15, 2025
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Dec 18, 2025

Study contacts

Lorenz von Seidlein
Contact
Lorenz@tropmedres.ac
+66926486322
Rupam Tripura
Contact
Rupam@tropmedres.ac
+8801572288558
Lorenz von Seidlein
principal investigator · Mahidol University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion